Cargando…

The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The aim of the study was to assess the effects of bevacizumab in augmenting trabeculectomy for glaucoma. We searched the databases of Cochrane Library, PubMed, Embase, CNKI, and VIP. All the databases were retrieved from the time databases established to September, 2015. The keywords we used were as...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Du, Liang, Li, Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839804/
https://www.ncbi.nlm.nih.gov/pubmed/27082560
http://dx.doi.org/10.1097/MD.0000000000003223
_version_ 1782428190742937600
author Liu, Xiaoyan
Du, Liang
Li, Ni
author_facet Liu, Xiaoyan
Du, Liang
Li, Ni
author_sort Liu, Xiaoyan
collection PubMed
description The aim of the study was to assess the effects of bevacizumab in augmenting trabeculectomy for glaucoma. We searched the databases of Cochrane Library, PubMed, Embase, CNKI, and VIP. All the databases were retrieved from the time databases established to September, 2015. The keywords we used were as follows: “bevacizumab,” “anti-VEGF,” “avastin,” “trabeculectomy,” “glaucoma,” and so on. We used a method of the freedom word search and the MeSH search combined, which was recommended by Cochrane Systematic Review Manual 5.1.2. Randomized controlled trails (RCTs) of frequently used bevacizumab in trabeculectomy for glaucoma were included. Study selection, data extraction, quality assessment, and data analysis were performed according to the Cochrane standards. Eight randomized controlled trails involving 212 eyes in the experimental (bevacizumab or bevacizumab + mitomycin C) groups and 214 eyes in the control (mitomycin C or placebo) groups were selected. Compared with placebo, bevacizumab significantly increased the complete success rate [OR = 2.79, 95%CI, (1.47, 5.29), P = 0.002], what else, bevacizumab also significantly decreased the intraocular pressure (IOP) [MD = 3.07, 95% CI, (0.87, 5.27), P = 0.006] at the 6-month after trabeculectomy and the number of antiglaucoma medications [MD = 1.23, 95% CI, (0.66, 1.80), P < 0.0001]. Additionally, it also increased the risk of bleb leak [OR = 5.24, 95% CI, (1.30, 21.10), P = 0.02]. When compared with mitomycin C (MMC), bevacizumab significantly increased the rate of encysted blebs [OR = 4.62, 95% CI, (1.02, 20.91), P = 0.05]. However, there was no significantly difference between the bevacizumab + MMC groups and MMC groups whatever the items were. Bevacizumab was an effective way in trabeculectomy concerning the complete success rate, IOP, and anti-glaucoma medications reduction when compared with placebo; however, it increased the risk of bleb leakage. And it significantly increased the rate of encysted blebs compared with MMC.
format Online
Article
Text
id pubmed-4839804
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-48398042016-06-02 The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Liu, Xiaoyan Du, Liang Li, Ni Medicine (Baltimore) 5800 The aim of the study was to assess the effects of bevacizumab in augmenting trabeculectomy for glaucoma. We searched the databases of Cochrane Library, PubMed, Embase, CNKI, and VIP. All the databases were retrieved from the time databases established to September, 2015. The keywords we used were as follows: “bevacizumab,” “anti-VEGF,” “avastin,” “trabeculectomy,” “glaucoma,” and so on. We used a method of the freedom word search and the MeSH search combined, which was recommended by Cochrane Systematic Review Manual 5.1.2. Randomized controlled trails (RCTs) of frequently used bevacizumab in trabeculectomy for glaucoma were included. Study selection, data extraction, quality assessment, and data analysis were performed according to the Cochrane standards. Eight randomized controlled trails involving 212 eyes in the experimental (bevacizumab or bevacizumab + mitomycin C) groups and 214 eyes in the control (mitomycin C or placebo) groups were selected. Compared with placebo, bevacizumab significantly increased the complete success rate [OR = 2.79, 95%CI, (1.47, 5.29), P = 0.002], what else, bevacizumab also significantly decreased the intraocular pressure (IOP) [MD = 3.07, 95% CI, (0.87, 5.27), P = 0.006] at the 6-month after trabeculectomy and the number of antiglaucoma medications [MD = 1.23, 95% CI, (0.66, 1.80), P < 0.0001]. Additionally, it also increased the risk of bleb leak [OR = 5.24, 95% CI, (1.30, 21.10), P = 0.02]. When compared with mitomycin C (MMC), bevacizumab significantly increased the rate of encysted blebs [OR = 4.62, 95% CI, (1.02, 20.91), P = 0.05]. However, there was no significantly difference between the bevacizumab + MMC groups and MMC groups whatever the items were. Bevacizumab was an effective way in trabeculectomy concerning the complete success rate, IOP, and anti-glaucoma medications reduction when compared with placebo; however, it increased the risk of bleb leakage. And it significantly increased the rate of encysted blebs compared with MMC. Wolters Kluwer Health 2016-04-18 /pmc/articles/PMC4839804/ /pubmed/27082560 http://dx.doi.org/10.1097/MD.0000000000003223 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5800
Liu, Xiaoyan
Du, Liang
Li, Ni
The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_fullStr The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_short The Effects of Bevacizumab in Augmenting Trabeculectomy for Glaucoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
title_sort effects of bevacizumab in augmenting trabeculectomy for glaucoma: a systematic review and meta-analysis of randomized controlled trials
topic 5800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839804/
https://www.ncbi.nlm.nih.gov/pubmed/27082560
http://dx.doi.org/10.1097/MD.0000000000003223
work_keys_str_mv AT liuxiaoyan theeffectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT duliang theeffectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT lini theeffectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT liuxiaoyan effectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT duliang effectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT lini effectsofbevacizumabinaugmentingtrabeculectomyforglaucomaasystematicreviewandmetaanalysisofrandomizedcontrolledtrials